

NS Miscellaneous



ADJOURNMENT OF COURT MEETING AND GENERAL MEETING

[IDOX PLC](#)

Released 07:26:21 12 December 2025

RNS Number : 2926L
IDOX PLC
12 December 2025

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

FOR IMMEDIATE RELEASE

12 December 2025

RECOMMENDED CASH ACQUISITION

of

Idox plc

by

Frankel UK Bidco Limited

(a newly-formed company indirectly owned by Long Path Co-Investment Fund #6, LP (acting by its general partner, Long Path Co-Investment Fund #6 GP, LLC), Long Path Smaller Companies Fund, LP (acting by its general partner Long Path Fund GP, LLC), Long Path Smaller Companies Master Fund, Ltd. and Long Path Opportunities Fund II, LP (acting by its general partner, Long Path Opportunities Fund GP, LLC))

to be effected by means of a scheme of arrangement under Part 26 of the Companies Act 2006

ADJOURNMENT OF COURT MEETING AND GENERAL MEETING

Introduction

On 28 October 2025, the boards of directors of Frankel UK Bidco Limited ("**Bidco**"), a newly-formed company to be indirectly owned by Long Path Co-Investment Fund #6, LP (acting by its general partner, Long Path Co-Investment Fund #6 GP, LLC), Long Path Smaller Companies Fund, LP (acting by its general partner Long Path Fund GP, LLC), Long Path Smaller Companies Master Fund, Ltd. and Long Path Opportunities Fund II, LP (acting by its general partner, Long Path Opportunities Fund GP, LLC), and Idox plc ("**Idox**") announced that they had reached agreement on the terms of a recommended cash acquisition for the entire issued, and to be issued, share capital of Idox by Bidco at a price of 71.5 pence per Idox Share (the "**Acquisition**") to be effected by means of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the "**Scheme**").

Idox published the circular relating to the Scheme on 20 November 2025 (the "**Scheme Document**"). Capitalised terms used but not defined in this announcement have the meanings given to them in the Scheme Document, unless the context requires otherwise. All references to time in this announcement are to London time, unless otherwise stated.

Court Meeting and General Meeting

The Idox Directors have reached the view that, in order to allow further time for discussions with Idox Shareholders, it is in the best interests of the Company and Idox Shareholders as a whole to adjourn the Court

Meeting and General Meeting which were originally scheduled to take place on 15 December 2025. Therefore, the Idox Directors have considered and agreed that the Chairman of Idox will use the discretion available to him to adjourn the Meetings. At the Meetings on 15 December 2025, the only business to be dealt with will be to adjourn the respective meetings to the times, date and location set out below. **Accordingly, the Idox Directors recommend that Idox Shareholders do not attend the Meetings on 15 December 2025.**

The Chair of the Meetings will adjourn the Court Meeting and General Meeting so they are instead held on 6 January 2026 at 10.00 a.m. and 10.15 a.m. (or as soon thereafter as the Court Meeting concludes or is further adjourned), respectively, at the offices of MHP Group at Ground Floor, 60 Great Portland Street, London W1W 7RT.

In respect of each Meeting, the relevant Forms of Proxy (or electronic appointment) should be received as soon as possible and in any event no later than:

BLUE Forms of Proxy for the Court Meeting: 10.00 a.m. on 2 January 2026; and

YELLOW Forms of Proxy for the General Meeting: 10.15 a.m. on 2 January 2026,

or, in the case of a further adjourned Meeting, not less than 48 hours (excluding any part of the day that is not a business day) before the time fixed for the further adjourned meeting.

If the blue Form of Proxy for the Court Meeting is not returned by the above time, it may be handed to the Chair of the Court Meeting or to Idox's registrars, Neville Registrars, on behalf of the Chair of the Court Meeting before the start of the Court Meeting. However, in the case of the General Meeting, if the yellow Form of Proxy for the General Meeting is not returned by the time mentioned above or not otherwise lodged in accordance with the instructions set out in the yellow Form of Proxy, it will be invalid.

Reconfirmation of the unanimous recommendation regarding the Revised Offer

The Idox Directors, who have been so advised by Rothschild & Co as to the financial terms of the Acquisition, continue to consider the terms of the Acquisition to be fair and reasonable. In providing its advice to the Idox Directors, Rothschild & Co has taken into account the commercial assessments of the Idox Directors. Rothschild & Co is providing independent advice to the Idox Directors for the purposes of Rule 3 of the Takeover Code. Accordingly, the Idox Directors reconfirm their unanimous recommendation that Voting Scheme Shareholders vote in favour of the Scheme at the Court Meeting and Idox Shareholders vote in favour of the Resolution relating to the Acquisition at the General Meeting.

No third party discussions

The Idox Directors confirm that the Company is not in discussions with any third parties regarding a potential competing offer.

Action to be taken

As further detailed in the Scheme Document, to become Effective, the Scheme will require, among other things, the approval of Scheme Shareholders at the Court Meeting and the passing of the Resolution at the General Meeting.

IT IS IMPORTANT THAT, FOR THE COURT MEETING, AS MANY VOTES AS POSSIBLE ARE CAST SO THAT THE COURT MAY BE SATISFIED THAT THERE IS A FAIR AND REASONABLE REPRESENTATION OF VOTING SCHEME SHAREHOLDER OPINION. VOTING SCHEME SHAREHOLDERS ARE THEREFORE STRONGLY URGED TO COMPLETE, SIGN AND RETURN YOUR FORMS OF PROXY (OR APPOINT A PROXY ELECTRONICALLY) OR TO APPOINT A PROXY THROUGH THE CREST ELECTRONIC PROXY APPOINTMENT SERVICE (AS APPROPRIATE) AS SOON AS POSSIBLE. DOING SO WILL NOT PREVENT YOU FROM ATTENDING, SPEAKING AND VOTING AT THE MEETINGS, OR ANY ADJOURNMENT THEREOF, IF YOU WISH AND ARE ENTITLED TO DO SO.

Idox Shareholders who DO NOT wish to change their voting instructions

Idox Shareholders who have already submitted Forms of Proxy, or who have appointed a proxy electronically using CREST, for the Court Meeting and the General Meeting and do not wish to change their voting instructions, need take no further action as their Forms of Proxy (or electronic appointment) will continue to be valid in respect of the Court Meeting and the General Meeting.

Idox Shareholders who DO wish to change their voting instructions

For Idox Shareholders who have already submitted Forms of Proxy, or who have appointed a proxy electronically using CREST, for the Court Meeting and the General Meeting and now wish to change their voting instructions should contact the shareholder helpline operated by Neville Registrars on +44 (0)121 585 1131. Calls to this number are charged at the standard geographic rate and will vary by provider. Calls from outside the UK will be charged at the applicable international rate. The helpline is open between 9.00 a.m. and 5.00 p.m. (London time), Monday to Friday, excluding public holidays in England and Wales. Please note that Neville Registrars cannot provide any financial, legal or tax advice nor provide any advice on the merits of the Scheme and calls may be recorded and monitored for security and training purposes

Revised Expected Timetable of Principal Events

An updated expected timetable for the Acquisition is set out in the Appendix of this announcement and, accordingly, the times and dates set out in the Expected Timetable of Principal Events in the Scheme Document and Forms of Proxy should be considered to be amended as set out in the Appendix of this announcement.

Enquiries

Bidco and Long Path

via Canaccord Genuity

Will Brennan

Brian Nelson

John Cresson

Kyle Warren

Canaccord Genuity Limited (Financial Adviser to Bidco and Long Path)

+ 44 (0) 20 7523 8000

Simon Bridges

Max Hartley

Harry Rees

+44 (0) 333 011 1200

Idox

333 011

1200

Chris Stone, Non-Executive Chair

David Meaden, Chief Executive Officer

Anoop Kang, Chief Financial Officer

N.M. Rothschild & Sons Limited (Lead Financial Adviser to Idox)

+44 (0) 20 7280 5000

Warner Mandel

Anton Black

Jose Benito Sanz

Peel Hunt LLP (Joint Financial Adviser and Corporate Broker to Idox)

+44 (0) 20 7418 8900

Neil Patel

Benjamin Cryer

Kate Bannatyne

Alice Lane

MHP (PR Adviser to Idox)

+ 44 (0) 783 140 6117

Reg Hoare

Ollie Hoare Finn Taylor

idox@mhpgroup.com

Kirkland & Ellis International LLP is acting as legal adviser to Bidco and Long Path.

Pinsent Masons LLP is acting as legal adviser to Idox.

Further information

Canaccord Genuity Limited, which is authorised and regulated by the FCA in the United Kingdom ("Canaccord"), is acting exclusively as financial adviser to Long Path and Bidco and no one else in connection with the Acquisition and will not be responsible to anyone other than Long Path and Bidco for providing the protections afforded to clients of Canaccord nor for providing advice in relation to the Acquisition or any other matters referred to in this announcement. Neither Canaccord nor any of its affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Canaccord in connection with this announcement, any statement contained herein or otherwise.

Rothschild & Co, which is authorised and regulated in the United Kingdom by the FCA, is acting exclusively as financial adviser to Idox and for no one else in connection with the subject matter of this announcement and will not be responsible to anyone other than Idox for providing the protections afforded to clients of Rothschild & Co nor for providing advice in connection with the Acquisition or any matter referred to in this announcement. Neither Rothschild & Co nor any of its group undertakings or affiliates (nor their respective directors, officers, employees or agents) owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Rothschild & Co in connection with this announcement, any statement contained herein, the Acquisition or otherwise. No representation or warranty, express or implied, is made by Rothschild & Co as to the contents of this announcement.

Peel Hunt LLP ("**Peel Hunt**"), which is authorised and regulated in the UK by the FCA, is acting as joint financial adviser and corporate broker to Idox in connection with the Acquisition and shall not be responsible to anyone other than Idox for providing the protections afforded to clients of Peel Hunt nor for providing advice in connection with the Acquisition or any matter referred to herein. Neither Peel Hunt nor any of its group undertakings or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Peel Hunt in connection with the Acquisition or any matter referred to herein.

This announcement is for information purposes only and is not intended to, and does not, constitute, or form part of, an offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the Acquisition or otherwise, nor shall there be any sale, issuance or transfer of securities of Idox in any jurisdiction in contravention of applicable law. The Acquisition will be implemented solely pursuant to the terms of the Scheme Document (or, if the Acquisition is implemented by way of an Offer, the offer document), which will contain the full terms and conditions of the Acquisition, including details of how to vote in respect of the Acquisition. Any vote in respect of the Scheme or other response in relation to the Acquisition should be made only on the basis of the information contained in the Scheme Document (or, if the Acquisition is implemented by way of an Offer, the offer document).

This announcement contains inside information in relation to Idox for the purposes of Article 7 of the Market Abuse Regulation. The person responsible for arranging the release of this announcement on behalf of Idox is Ruth Paterson, Company Secretary of Idox. Idox's Legal Entity Identifier is 213800Z3FE6PWVSUGE70.

This announcement does not constitute a prospectus, prospectus equivalent document or exempted document.

If you are in any doubt about the contents of this announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent financial adviser duly authorised under the Financial Services and Markets Act 2000 (as amended) if you are resident in the United Kingdom or, if not, from another appropriately authorised independent financial adviser.

Idox urges Idox Shareholders to read the Scheme Document as it contains important information relating to the Acquisition.

Overseas Shareholders

The release, publication or distribution of this announcement in or into jurisdictions other than the UK may be restricted by law and therefore any persons who are subject to the law of any jurisdiction other than the UK should inform themselves of, and observe, any applicable legal or regulatory requirements. Any failure to comply with such requirements may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, the companies and persons involved in the Acquisition disclaim any responsibility or liability for the violation of such restrictions by any person. This announcement has been prepared in accordance with and for the purpose of complying with English law, the Takeover Code, the AIM Rules, the Market Abuse Regulation and the Disclosure Guidance and Transparency Rules and information disclosed may not be the same as that which would have been prepared in accordance with the laws of jurisdictions outside England.

The availability of the Acquisition to Idox Shareholders who are not resident in and citizens of the UK may be affected by the laws of the relevant jurisdictions in which they are located or of which they are citizens. Persons who are not resident in the UK should inform themselves of, and observe, any applicable legal or regulatory requirements of their jurisdictions. Any person (including, without limitation, nominees, trustees and custodians) who would, or otherwise intends to, forward this announcement, the Scheme Document or any accompanying document to any jurisdiction outside the UK should refrain from doing so and seek appropriate professional advice before taking any action. In particular, the ability of persons who are not resident in the United Kingdom to vote their Idox Shares with respect to the Scheme at the Court Meeting, or to appoint another person as proxy to vote at the Court Meeting on their behalf, may be affected by the laws of the relevant jurisdictions in which they are located. Any failure to comply with the applicable restrictions may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, the companies and persons involved in the Acquisition disclaim any responsibility or liability for the violation of such restrictions by any person. Further details in relation to Overseas Shareholders will be contained in the Scheme Document (or, if the Acquisition is implemented by way of an Offer, the offer document).

Unless otherwise determined by Bidco or required by the Takeover Code, and permitted by applicable law and regulation, the Acquisition will not be made available, directly or indirectly, in, into, from, or by the use of mails or any means or instrumentality (including, but not limited to, facsimile, e-mail or other electronic transmission, telex or telephone) of interstate or foreign commerce of, or of any facility of a national, state or other securities exchange of, any Restricted Jurisdiction where to do so would violate the laws in that jurisdiction and no person may vote in favour of the Scheme by any such use, means, instrumentality or from within a Restricted Jurisdiction or any other jurisdiction if to do so would constitute a violation of the laws of that jurisdiction. Copies of this announcement and any formal documentation relating to the Acquisition are not being, and must not be, directly or indirectly, mailed or otherwise forwarded, distributed or sent in or into or from any Restricted Jurisdiction and persons receiving such documents (including, without limitation, agents, custodians, nominees and trustees) must not mail or otherwise forward, distribute or send it in or into or from any Restricted Jurisdiction. Doing so may render invalid any related purported vote in respect of the Acquisition. If the Acquisition is implemented by way of an Offer (unless otherwise permitted by applicable law and regulation), the Offer may not be made directly or indirectly, in, into, from, or by the use of mails or any means or instrumentality (including, but not limited to, facsimile, e-mail or other electronic transmission, telex or telephone) of interstate or foreign commerce of, or of any facility of a national, state or other securities exchange of, any Restricted Jurisdiction and the Offer may not be capable of acceptance by any such use, means, instrumentality or facilities.

Further details in relation to Overseas Shareholders will be included in the Scheme Document (or, if the Acquisition is implemented by way of an Offer, the offer document).

Notice to U.S. Idox Shareholders

The Acquisition relates to the shares of an English company and is being made by means of a scheme of arrangement provided for under English law. A transaction effected by means of a scheme of arrangement is not subject to the tender offer or proxy solicitation rules under the U.S. Exchange Act. Accordingly, the Acquisition is subject to the disclosure requirements and practices applicable in the UK to schemes of arrangement which differ from the disclosure requirements of the U.S. tender offer and proxy solicitation rules. The financial information included in this announcement has been prepared in accordance with generally accepted accounting principles of the United Kingdom and thus may not be comparable to financial information of U.S. companies or companies whose financial statements are prepared in accordance with generally accepted accounting principles in the United States.

If, in the future, Bidco exercises its right to implement the Acquisition by way of an Offer, which is to be made into the United States, such Offer will be made in compliance with the applicable U.S. laws and regulations.

It may be difficult for U.S. holders of Idox Shares to enforce their rights and any claim arising out of the U.S. federal laws, since Bidco and Idox are located in a non-U.S. jurisdiction, and some or all of their officers and directors may be residents of a non-U.S. jurisdiction. U.S. holders of Idox may not be able to sue a non-U.S. company or its officers or directors in a non-U.S. court for violations of the U.S. securities laws. Further, it may be difficult to compel a non-U.S. company and its affiliates to subject themselves to a U.S. court's judgement.

In accordance with normal UK practice and pursuant to Rule 14e-5(b) of the U.S. Exchange Act, Long Path or their nominees, or their brokers (acting as agents), may from time to time make certain purchases of, or arrangements to purchase, Idox Shares outside of the U.S., other than pursuant to the Acquisition, until the date on which the Acquisition becomes Effective, lapses or is otherwise withdrawn. Also, in accordance with Rule 14e-5(b) of the U.S. Exchange Act, Canaccord will continue to act as an exempt principal trader in Idox Shares on the London Stock Exchange. These purchases may occur either in the open market at prevailing prices or in private transactions at negotiated prices. Any information about such purchases will be disclosed as required in the United Kingdom, will be reported to a Regulatory Information Service and will be available on the London Stock Exchange website, www.londonstockexchange.com.

U.S. Idox Shareholders also should be aware that the transaction contemplated herein may have tax consequences for U.S. federal income tax purposes and under applicable U.S. state and local, as well as foreign and other, tax laws and, that such consequences, if any, are not described herein. U.S. Idox Shareholders are urged to consult with legal, tax and financial advisers in connection with making a decision regarding this transaction.

Disclosure requirements of the Takeover Code

Under Rule 8.3(a) of the Takeover Code, any person who is interested in 1 per cent. or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 p.m. (London time) on the 10th Business Day following the commencement of the offer period and, if appropriate, by no later than 3.30 p.m. (London time) on the 10th Business Day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Takeover Code, any person who is, or becomes, interested in 1 per cent. or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 p.m. (London time) on the Business Day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at <http://www.thetakeoverpanel.org.uk>, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

Publication on Website and Availability of Hard Copies

This announcement and the documents required to be published pursuant to Rule 26.1 of the Code and pursuant to Rule 26 of the AIM Rules for Companies will be available free of charge, subject to certain restrictions relating to persons resident in Restricted Jurisdictions, on the investor relations section of Idox's website

at <http://www.idoxgroup.com/investors/> by no later than 12.00 noon (London time) on the Business Day following the date of this announcement.

Neither the content of any website referred to in this announcement nor the content of any website accessible from hyperlinks is incorporated into, or forms part of, this announcement.

In accordance with Rule 30.3 of the Code, Idox Shareholders, persons with information rights and participants in the Idox Share Plan may request a hard copy of this announcement by: (i) contacting Idox's Registrar, Neville Registrars, during business hours on 0121 585 1131 if calling from the United Kingdom, or +44 (0) 0121 585 1131 if calling from outside the United Kingdom (lines are open from 9.00 a.m. to 5.00 p.m., Monday to Friday (excluding public holidays in England and Wales)); or (ii) by submitting a request in writing to Neville Registrars, Neville House, Steelpark Road, Halesowen B62 8HD. A person so entitled may also request that all future documents, announcements and information in relation to the Acquisition be sent to them in hard copy form.

Electronic Communications

Please be aware that addresses, electronic addresses and certain other information provided by Idox Shareholders, persons with information rights, and other relevant persons for the receipt of communications from Idox may be provided to Bidco during the Offer Period as required under Section 4 of Appendix 4 of the Code in order to comply with Rule 2.11(c) of the Code.

APPENDIX

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

The following indicative timetable is based on Idox's and Frankel's current expectations for the implementation of the Scheme in view of the proposed adjournment and is subject to change. If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Idox Shareholders by announcement through a Regulatory Information Service. If the Court Meeting or General Meeting is adjourned again or the Court Hearing is adjourned, or the Idox Board decides to propose such an adjournment, then Idox Shareholders will be notified of the same by announcement through a Regulatory Information Service (and, if adjourned to a specified date, such details will be set out in the announcement).

Event	Expected time / date ⁽¹⁾
Latest time for lodging Forms of Proxy for the:	
Court Meeting (BLUE form)	10.00 a.m. on 2 January 2026 ⁽²⁾
General Meeting (YELLOW form)	10.15 a.m. on 2 January 2026 ⁽³⁾
Voting Record Time	6.00 p.m. on 2 January 2026 ⁽⁴⁾
Court Meeting	10.00 a.m. on 6 January 2026
General Meeting	10.15 a.m. on 6 January 2026⁽⁵⁾
The following dates will be determined by the date of satisfaction of the Conditions; please see note (6) below.	
Court Hearing	A date expected to be before the end of Q1 2026 ("D")
Last day of dealings in, or for registration of transfers of, and disablement in CREST of Idox Shares	D
Scheme Record Time	6.00 p.m. on D
Dealings in Idox Shares suspended	7.30 a.m. on D+1 business day
Effective Date of the Scheme	D+1 business day⁽⁷⁾
Cancellation of admission to trading of Idox Shares on AIM	7.00 a.m. on D+2 business days
Despatch of cheques and crediting of CREST for Consideration due under the Scheme	At or soon after 8.00 a.m. on D+2 (but not later than 14 days after the Effective Date)

Long-stop Date	30 June 2026 ⁽⁸⁾
----------------	-----------------------------

(1) The dates and times given are indicative only and are based on current expectations and are subject to change (including as a result of changes to the regulatory timetable). References to times are to London, United Kingdom time unless otherwise stated. If any of the times and/or dates above change, the revised times and/or dates will be notified to Idox Shareholders by announcement through a Regulatory Information Service.

(2) It is requested that blue Forms of Proxy for the Court Meeting be lodged not later than 48 hours prior to the time fixed for the adjourned Court Meeting (excluding any part of such 48-hour period falling on a day that is not a Business Day). If the blue Form of Proxy for the adjourned Court Meeting is not lodged by 10.00 a.m. on 2 January 2026, it may be presented in person to the chair of the Court Meeting or the Neville representative who will be present at the Court Meeting any time prior to the commencement of the Court Meeting (or any adjournment thereof).

(3) In order to be valid, the yellow Forms of Proxy for the adjourned General Meeting must be lodged not later than 10.15 a.m. on 2 January 2026 or, if the General Meeting is adjourned, 48 hours prior to the time fixed for the adjourned General Meeting (excluding any part of such 48-hour period falling on a day that is not a business day).

(4) If either the Court Meeting or the General Meeting is adjourned again, the Voting Record Time for the relevant adjourned meeting will be 6.00 p.m. on the day which is two business days prior to the date of the adjourned Meeting.

(5) To commence at 10.15 a.m. or as soon thereafter as the Court Meeting concludes or is adjourned.

(6) The following dates and times associated with the Scheme are subject to change and will depend on, among other things, the date on which the Conditions to the Scheme are satisfied or, if capable of waiver, waived, and the date on which the Court sanctions the Scheme. Idox will give adequate notice of any changes to these dates and times, when known, by issuing an announcement through a Regulatory Information Service, with such announcement being made available on Idox's website at <http://www.idoxgroup.com/investors/>. Further updates and changes to these times will be notified in the same way. See also note (1).

(7) The parties expect that, subject to the satisfaction (or, where applicable, waiver) of the Conditions in Part Three (*Conditions and Further Terms of the Acquisition*) of the Scheme Document, the Scheme will become Effective before the end of Q1 2026.

(8) This is the latest date by which the Scheme may become Effective. However, the Long Stop Date may be extended to such later date as may be agreed by Idox and Bidco (with the Panel's consent and as the Court may approve (if such consent and/or approval is required)) or if the Panel requires an extension to the Long Stop Date pending final determination of an issue under section 3(g) of Appendix 7 of the Takeover Code.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.